Achieved sequential improvement in net sales
and profitability
Increases full year 2020 guidance for net
sales and Adjusted EBITDA
Retired $24.5 million of convertible notes
due in 2021
Invacare Corporation (NYSE: IVC) ("Invacare" or the "company")
today reported results for the quarter ended September 30,
2020.
Key Metrics (3Q20 versus 3Q19, except as noted*)
- Reported net sales were down 10.1% to $211.9 million, while
constant currency net sales(a), which excludes the 1Q20 Dynamic
Controls divestiture, decreased 10.0%.
- Revenue growth in respiratory products was more than offset by
lower sales in mobility and seating and lifestyle products.
- Sales of mobility and seating and lifestyle products continue
to be impacted by the pandemic, with public health measures in
certain geographies limiting access to healthcare professionals and
institutions needed for certain product selections, and limited
access to long-term care facilities.
- Reported net sales increased sequentially from 2Q20 by 8.0%,
driven primarily by Europe mobility and seating products, which
grew 38.4%. Constant currency sequential net sales(b) increased
4.3%, with growth in mobility and seating products of 17.6% offset
by lower sales of lifestyle products, primarily bed and bed-related
products.
- Gross profit as a percent of net sales decreased 40 basis
points compared to the prior year to 28.3%, attributable to
unfavorable manufacturing variances associated with reduced net
sales compared to 3Q19, primarily in Europe.
- Reported SG&A expenses improved by $8.0 million, or 12.6%,
and constant currency SG&A(c) improved by $7.8 million, or
12.5%, driven primarily by reduced employment costs, lower
commercial expenses and favorable foreign exchange.
- Operating income improved by $0.5 million, or 21.2%, to $2.9
million, driven by reduced SG&A expenses partially offset by
lower gross profit as result of reduced net sales.
- GAAP loss per share was $0.21 compared to a loss per share of
$0.24. Adjusted net loss per share(e) was $0.10 compared to
adjusted net loss per share of $0.15.
- Adjusted EBITDA(f) improved by $0.2 million, or 2.5%, to $9.8
million driven by reduced SG&A expenses, which represents the
12th consecutive quarter of year-over-year improvement.
- Free cash flow(g) usage was $1.8 million, a decrease of $14.1
million compared to free cash flow generation in 3Q19, primarily
due to net cash used by operating activities supporting working
capital needs. Sequentially as compared to 2Q20, free cash flow
usage improved $0.1 million, due to higher profitability and lower
inventory, offset by reduced accounts payable. Sequential increase
in revenue resulted in increased account receivable as well.
* Date format is quarter and year in each instance
Key Financial Results (3Q20 versus 3Q19)
(in millions USD)
3Q20
3Q19
$ Change
Fav/(Unfav)
% Change
Fav/(Unfav)
Net Sales
$211.9
$235.8
$(23.9)
(10.1)%
Constant Currency Net Sales (1)
$208.8
$232.0
$(23.2)
(10.0)%
Gross Profit % of Net Sales
28.3%
28.7%
(40 bps)
Gross Profit
$60.0
$67.6
$(7.5)
(11.2)%
Reported SG&A
$55.5
$63.5
$8.0
12.6%
Constant Currency SG&A (1)
$54.7
$62.5
$7.8
12.5%
Operating Income
$2.9
$2.4
$0.5
21.2%
Adjusted EBITDA
$9.8
$9.6
$0.2
2.5%
Free Cash Flow
$(1.8)
$12.3
$(14.1)
--
(1) Based on 3Q19 FX rates
Key Financial Results (3Q20 versus 2Q20)
(in millions USD)
3Q20
2Q20
$ Change
Fav/(Unfav)
% Change
Fav/(Unfav)
Net Sales
$211.9
$196.3
$15.6
8.0%
Constant Currency Sequential Net Sales
(2)
$204.8
$196.3
$8.5
4.3%
Gross Profit % of Net Sales
28.3%
28.9%
(60 bps)
Gross Profit
$60.0
$56.7
$3.4
6.0%
Reported SG&A
$55.5
$57.4
$1.9
3.3%
Constant Currency Sequential SG&A (d),
(2)
$54.0
$57.4
$3.4
6.0%
Operating Income (Loss)
$2.9
$(2.2)
$5.2
--
Adjusted EBITDA
$9.8
$6.6
$3.2
48.7%
Free Cash Flow
$(1.8)
$(1.9)
$0.1
3.2%
(2) Based on 2Q20 FX rates
Executive Summary
"I am pleased with our 3Q20 performance which reflects
sequential improvement in net sales and a nearly 49% sequential
increase in profitability, despite the continuing pandemic. We
successfully achieved our 12th consecutive quarter of higher
year-over-year quarterly Adjusted EBITDA growth by taking actions
to leverage SG&A expenses, mitigate supply chain constraints,
and introduce new products which are expected to drive incremental
sales growth. In addition, our transformation initiatives have
driven sustainable improved results in line with our expectations,
and we remain poised to continue delivering stronger results even
as we navigate the challenging environment," commented Matt
Monaghan, chairman, president and chief executive officer.
"In Europe, we were encouraged by double-digit improvement in
sequential net sales as public health restrictions began to ease,
reflecting returning demand during this initial phase of the
recovery. Looking ahead, we are seeing positive momentum in sales
in our key countries of France and Germany, with the UK remaining
relatively closed. As markets continue to re-open, we anticipate
this will have a positive impact on net sales, however,
pandemic-related closures are unpredictable and may occur
intermittently over the winter months, but are not expected to be
as severe as those enacted in 2Q20.
At the same time, our North America business remained resilient,
demonstrated by both year-over-year and sequential improvement in
net sales, and a $4.7 million improvement in operating income
compared to the prior year. For respiratory products, demand
remained elevated as the pandemic persisted, and we expect this
trend to continue but return to a more normalized level of sales.
Due to the longer quote-to-order cycle, primarily in the United
States, sales of mobility and seating products were impacted as
public health restrictions in 2Q20 limited end user assessments and
dampened quotes. However, as restrictions eased, we experienced
significantly higher quotes in 3Q20, which we expect will be
converted into stronger sales in 4Q20.
Meanwhile, we continue to make great progress on our 2020 and
long-term transformational initiatives which will simplify the
business and improve margins. Our global IT modernization and plant
consolidation in Germany remain on track. Assuming that markets
begin to normalize in 2021, we expect these efficiencies and the
increased acceptance of new products will drive incremental sales
growth beyond pre-pandemic levels, accelerating our already
improving operating results," concluded Monaghan.
Kathy Leneghan, senior vice president and chief financial
officer stated, "As guided, we achieved constant currency
sequential net sales improvement while Adjusted EBITDA improved
both year-over-year and sequentially. Free cash flow usage in the
quarter of $1.8 million was impacted by reduced accounts payable
and increased accounts receivable, which should largely be
collected in 4Q20. In addition, we took further actions to improve
our balance sheet by retiring $24.5 million of convertible notes
due in 2021 at a slight aggregate discount to par, leaving less
than $1.3 million maturing in February 2021. We remain confident
that our increasingly flexible balance sheet will support us
through the transformation, and as always, we continue to assess
opportunities to further optimize our capital structure."
Updated Full Year 2020 Guidance
Consolidated net sales are expected to improve sequentially, but
remain lower than prior year, based on continuing access to
healthcare facilities without new public health restrictions, and
from increased adoption of new products. While the markets are
expected to continue to remain open, pandemic-related closures may
vary over the winter months. Given the timing of the recognition of
sequential improvements in sales during the fourth quarter, the
company anticipates increased free cash flow usage for the full
year as a result of timing in collection of cash until 1Q21.
As a result of the sequential improvement in the business
performance achieved in the third quarter and visibility into the
early months of the fourth quarter, for the full-year 2020, the
company now expects:
- Reported net sales of at least $840 million, up from previous
range of $810 to $840 million;
- Adjusted EBITDA in the range of $28 to $32 million, up from
previous range of $27 to $30 million; and
- Free cash flow usage in the range of $8 to $12 million, changed
from previous range of $7 to $10 million.
3Q20 Segment Results versus 3Q19
(in millions USD)
Net Sales
Operating Income
(Loss)
3Q20
3Q19
Reported
% Change
Constant
Currency
% Change
3Q20
3Q19
% Change
Europe
$
116.3
$
137.4
(15.3
)%
(17.5
)%
$
7.6
$
11.4
(33.1
)%
North America
88.1
87.1
1.1
1.2
3.0
(1.7
)
--
All Other
7.6
11.3
(33.0
)
(3.1
)
(6.1
)
(5.6
)
(8.1
)
Europe - Constant currency net sales decreased 17.5% as
sales continued to be impacted by the pandemic and with public
health restrictions in certain countries continuing to limit access
to healthcare professionals and institutions needed for certain
product selections. These measures lowered sales for mobility and
seating products most significantly, and, to a lesser extent,
non-bed lifestyle products, and were partially offset by growth in
bed systems and respiratory products. Gross profit declined by $8.1
million, or 230 basis points, due to reduced net sales and
unfavorable operational variances, as a result of the pandemic.
Operating income was $7.6 million, a decrease of $3.8 million due
to reduced gross profit as result of lower net sales partially
offset by reduced SG&A expenses.
North America - Constant currency net sales increased
1.2% driven by respiratory products, partially offset by lower
sales of mobility and seating and non-bed lifestyle products, which
continue to be adversely impacted by pandemic-related public health
restrictions. In addition, both power and manual wheelchair net
sales were lower due to reduced levels of quotes for these products
in the early part of 2Q20, which would normally convert to sales in
3Q20. As a result of significantly higher quote levels in 3Q20
compared to 2Q20, sales of mobility and seating products are
expected to accelerate in 4Q20. Gross profit improved $2.6 million,
or 170 basis points, driven by net sales growth, reduced material
and freight costs, partially offset by unfavorable operational
variances and warranty expense. Operating income improved by $4.7
million primarily due to the benefit of increased gross profit and
reduced SG&A expenses.
All Other - Constant currency net sales in the Asia
Pacific region decreased 3.1% due to lower sales of mobility and
seating products and service revenue, partially offset by growth in
lifestyle products. Operating loss for All Other includes the
operating income of the Asia Pacific business, offset by
unallocated SG&A expenses and intercompany eliminations.
Operating loss for All Other increased $0.5 million primarily as a
result of the Dynamic Controls divestiture in 1Q20.
3Q20 Segment Results versus 2Q20
(in millions USD)
Net Sales
Operating Income
(Loss)
3Q20
2Q20
Reported
% Change
Sequential
Constant
Currency
% Change
3Q20
2Q20
% Change
Europe
$
116.3
$
101.9
14.1
%
8.0
%
$
7.6
$
2.2
249.6
%
North America
88.1
86.6
1.7
1.3
3.0
4.8
(37.8
)
All Other
7.6
7.8
(3.5
)
(10.3
)
(6.1
)
(7.7
)
21.4
Europe - Constant currency sequential net sales increased
8.0% driven by a 30.4% increase in mobility and seating products
partially offset by lower sales of in lifestyle products, primarily
bed and bed-related products, with respiratory product sales flat.
Operating income improved $5.4 million primarily due to increased
gross profit driven by increased net sales, including favorable
product mix due to higher sales of mobility and seating products,
and favorable foreign exchange, partially offset by unfavorable
manufacturing variances.
North America - Constant currency sequential net sales
increased 1.3% primarily driven by growth in non-bed lifestyle
products. Operating income decreased $1.8 million primarily due to
increased SG&A expenses and lower gross margin driven by a
return to more normal acuity product mix.
All Other - Constant currency sequential net sales
declined 10.3% primarily due to lifestyle products. Operating loss
for All Other includes the operating income of the Asia Pacific
business, offset by unallocated SG&A expenses and intercompany
eliminations. Operating loss for All Other decreased $1.7 million
primarily as a result of reduced SG&A expenses, driven by lower
stock compensation, partially offset by lower operating income of
the Asia Pacific business due to lower net sales.
Financial Condition
The company's cash and cash equivalents balances were $86.8
million and $80.1 million at September 30, 2020, and December 31,
2019, respectively. The change was primarily the result of cash
borrowed on the bank credit facility and the proceeds from the
divestiture of Dynamic Controls partially offset by cash used to
fund operations and debt payments, including the retirement of
$24.5 million in convertible notes during 3Q20.
Free cash flow usage of in 3Q20 was $1.8 million, unfavorable by
$14.1 million as compared to free cash flow generated in 3Q19. The
change was primarily due to net cash used for operating activities
supporting working capital needs primarily in accounts receivable
and accounts payable. While capital expenditures increased related
primarily to the ERP implementation, this was offset in a benefit
in accrued expenses. Free cash flow usage in 3Q20 was also impacted
by the timing of revenue recognized during the quarter which
increased accounts receivable at the end of the quarter.
Sequentially, free cash flow usage improved by $0.1 million as a
result of higher profitability and lower inventory, offset by
increased accounts receivable from sequential sales growth, and
reduced accounts payable.
Conference Call and Webcast
As previously announced, the company will provide a conference
call and webcast for investors and other interested parties to
review its third quarter 2020 financial results on Friday, October
30, 2020 at 8:30 AM ET. Those wishing to participate in the live
call should dial 800-458-4121, or for international callers
786-789-4772, and enter Conference ID 8637884. A simultaneous
webcast of the call will be accessible at
https://ctevents.webex.com. A copy of the webcast slide deck will
be posted to www.invacare.com/investorrelations prior to the
webcast.
A recording of the conference call can be accessed by dialing
888-203-1112 (U.S. and Canada) or 719-457-0820 (international
callers) and entering the Conference ID Code 8637884 and PIN 6529,
through November 6, 2020. An archive of the webcast presentation
will be posted at www.invacare.com/investorrelations 24 hours after
the call.
Upcoming Investor Events
- December 2, 2020 - Piper Sandler Healthcare Conference
(virtual)
- December 9, 2020 - Lytham Partners Conference (virtual)
- January 13, 2021 - CJS New Ideas for the New Year Conference
(virtual)
- January 14, 2021 - Needham Growth Conference
(virtual)
About Invacare Corporation
Invacare Corporation (NYSE: IVC) ("Invacare" or the "company")
is a leading manufacturer and distributor in its markets for
medical equipment used in non-acute care settings. At its core, the
company designs, manufactures and distributes medical devices that
help people to move, breathe, rest, and perform essential hygiene.
The company provides clinically complex medical device solutions
for congenital (e.g., cerebral palsy, muscular dystrophy, spina
bifida), acquired (e.g., stroke, spinal cord injury, traumatic
brain injury, post-acute recovery, pressure ulcers) and
degenerative (e.g., ALS, multiple sclerosis, chronic obstructive
pulmonary disease (COPD), elderly, bariatric) ailments. The
company's products are important parts of care for people with a
wide range of challenges, from those who are active and involved in
work or school each day and may need additional mobility or
respiratory support, to those who are cared for in residential care
settings, at home and in rehabilitation centers. The company sells
its products principally to home medical equipment providers with
retail and e-commerce channels, residential care operators,
distributors, and government health services in North America,
Europe, and Asia/Pacific. For more information about the company
and its products, visit Invacare's website at www.invacare.com.
This press release contains forward-looking statements within
the meaning of the “Safe Harbor” provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are those that describe future outcomes or expectations
that are usually identified by words such as “will,” “should,”
“could,” “plan,” “intend,” “expect,” “continue,” “forecast,”
“believe,” and “anticipate” and include, for example, statements
related to the expected effects on the company’s business of the
COVID-19 pandemic; sales and free cash flow trends; the impact of
contingency plans and cost containment actions; the company’s
liquidity and working capital expectations; the company’s future
financial results; and similar statements. Actual results may
differ materially as a result of various risks and uncertainties,
including the duration and scope of the COVID-19 pandemic, the
resumption of access to healthcare, including clinics and elective
care, and loosening of public health restrictions, or any reimposed
restrictions on access to health care or tightening of public
health restrictions and impact on the demand for the company’s
products; the ability of the company to obtain needed raw materials
and components from its suppliers; actions that governments,
businesses and individuals take in response to the pandemic,
including mandatory business closures and restrictions on onsite
commercial interactions; the impact of the pandemic and actions
taken in response to the pandemic on global and regional economies
and economic activity; the pace of recovery when the COVID-19
pandemic subsides; general economic uncertainty in key global
markets and a worsening of global economic conditions or low levels
of economic growth; the effects of steps the company takes to
reduce operating costs; the inability of the company to sustain
profitable sales growth, achieve anticipated improvements in
segment operating performance, convert high inventory or accounts
receivable levels to cash or reduce its costs to maintain
competitive prices for its products; lack of market acceptance of
the company's new product innovations; circumstances or
developments that may make the company unable to implement or
realize the anticipated benefits, or that may increase the costs,
of its current and planned business initiatives, in particular the
key elements of its enhanced transformation and growth plan such as
its new product introductions, additional investments in sales
force and demonstration equipment, plant consolidation in Germany,
supply chain actions and global information technology outsourcing
and ERP implementation activities; possible adverse effects on the
company's liquidity, including the company's ability to address
future debt maturities, that may result from delays in the
implementation of, any failure to realize benefits from, its
current and planned business initiatives; adverse changes in
government and third-party payor reimbursement levels and practices
in the U.S.; adverse impacts of new tariffs or increases in
commodity prices or freight costs; regulatory proceedings or the
company's failure to comply with regulatory requirements or receive
regulatory clearance or approval for the company's products or
operations; adverse effects of regulatory or governmental
inspections of the company's facilities at any time and
governmental investigations or enforcement actions; exchange rate
fluctuations; and those other risks and uncertainties expressed in
the cautionary statements and risk factors in the company's annual
report on Form 10-K, quarterly reports on Form 10-Q and other
filings with the Securities and Exchange Commission. The company
may not be able to predict and may have little or no control over
many factors or events that may influence its future results and,
except as required by law, shall have no obligation to update any
forward-looking statements.
INVACARE CORPORATION AND
SUBSIDIARIES
CONDENSED CONSOLIDATED
STATEMENT OF INCOME (LOSS) - (UNAUDITED)
(In thousands, except per share data)
Three Months Ended
Nine Months Ended
September 30
September 30
2020
2019
2020
2019
Net sales
$
211,906
$
235,774
$
626,646
$
695,051
Cost of products sold
151,866
168,189
446,968
500,945
Gross Profit
60,040
67,585
179,678
194,106
Selling, general and administrative
expenses
55,530
63,539
174,672
197,035
Gain on sale of business
—
—
(9,790
)
—
Charges related to restructuring
activities
1,580
1,628
4,657
3,641
Operating Income (Loss)
2,930
2,418
10,139
(6,570
)
Net gain on convertible debt
derivatives
—
—
—
(1,197
)
Loss on debt extinguishment including debt
finance charges and fees
761
280
7,360
280
Interest expense - net
7,395
6,879
21,042
21,666
Loss before Income Taxes
(5,226
)
(4,741
)
(18,263
)
(27,319
)
Income tax provision
2,050
3,300
4,900
7,325
Net Loss
(7,276
)
(8,041
)
(23,163
)
(34,644
)
Net Loss per Share—Basic
$
(0.21
)
$
(0.24
)
$
(0.68
)
$
(1.03
)
Weighted Average Shares
Outstanding—Basic
34,419
33,660
34,213
33,571
Net Loss per Share—Assuming Dilution
*
$
(0.21
)
$
(0.24
)
$
(0.68
)
$
(1.03
)
Weighted Average Shares
Outstanding—Assuming Dilution
34,530
33,668
34,313
33,581
* Net loss per share assuming dilution calculated using weighted
average shares outstanding - basic for periods in which there is a
loss.
INVACARE CORPORATION AND
SUBSIDIARIES
RECONCILIATION OF NET INCOME
(LOSS) PER SHARE
TO ADJUSTED NET LOSS PER
SHARE(e)
(In thousands, except per share data)
Three Months Ended
Nine Months Ended
September 30
September 30
2020
2019
2020
2019
Net Loss per share - assuming
dilution*
$
(0.21
)
$
(0.24
)
$
(0.68
)
$
(1.03
)
Weighted average shares outstanding-
assuming dilution
34,419
33,660
34,213
33,571
Net Loss
(7,276
)
(8,041
)
(23,163
)
(34,644
)
Income tax provision
2,050
3,300
4,900
7,325
Loss Before Income Taxes
(5,226
)
(4,741
)
(18,263
)
(27,319
)
Amortization of discount on convertible
debt
3,035
2,764
8,629
9,429
Gain on sale of business
—
—
(9,790
)
—
Net gain on convertible debt
derivatives
—
—
—
(1,197
)
Loss on debt extinguishment including debt
finance charges and associated fees
761
280
7,360
280
Adjusted Loss Before Income
Taxes
(1,430
)
(1,697
)
(12,064
)
(18,807
)
Adjusted Income Taxes
2,050
3,300
5,888
7,325
Adjusted Net Loss(h)
$
(3,480
)
$
(4,997
)
$
(17,952
)
$
(26,132
)
Weighted Average Shares Outstanding -
Assuming Dilution
34,419
33,660
34,213
33,571
Adjusted Net Loss per Share(e) -
Assuming Dilution*
$
(0.10
)
$
(0.15
)
$
(0.52
)
$
(0.78
)
"Adjusted net loss per share" and "adjusted net loss" are
non-GAAP financial measures, which are defined at the end of this
press release.
*Net loss per share assuming dilution and adjusted net loss per
share(e) assuming dilution are calculated using weighted average
shares outstanding - basic for periods in which there is a
loss.
INVACARE CORPORATION AND
SUBSIDIARIES
RECONCILIATION OF NET INCOME
(LOSS) TO ADJUSTED EBITDA(f)
Three Months Ended
Nine Months Ended
(In thousands)
September 30
September 30
2020
2019
2020
2019
Net Loss
$
(7,276
)
$(8,041
)
$
(23,163
)
$
(34,644
)
Income tax provision
2,050
3,300
4,900
7,325
Interest expense - net
7,395
6,879
21,042
21,666
Loss on debt extinguishment including debt
finance charges and associated fees
761
280
7,360
280
Net gain on convertible debt
derivatives
—
—
—
(1,197
)
Operating Income (Loss)
2,930
2,418
10,139
(6,570
)
Gain on sale of business
—
—
(9,790
)
—
Depreciation and amortization
3,700
3,991
10,360
11,800
EBITDA
6,630
6,409
10,709
5,230
Charges related to restructuring
activities
1,580
1,628
4,657
3,641
Share-based compensation expense
1,639
1,570
6,965
5,873
Adjusted EBITDA(f)
$
9,849
$9,607
$
22,331
$
14,744
Three Months Ended
(In thousands)
September 30
June 30
2020
2020
Net Loss
$
(7,276
)
$
(16,619
)
Income tax provision
2,050
750
Interest expense - net
7,395
7,031
Loss on debt extinguishment including debt
finance charges and associated fees
761
6,599
Operating Income (Loss)
2,930
(2,239
)
Gain on sale of business
—
(200
)
Depreciation and amortization
3,700
3,253
EBITDA
6,630
814
Charges related to restructuring
activities
1,580
1,685
Share-based compensation expense
1,639
4,126
Adjusted EBITDA(f)
$
9,849
$
6,625
"Adjusted EBITDA(f)" is a non-GAAP financial measure, which is
defined at the end of this press release.
INVACARE CORPORATION AND SUBSIDIARIES
BUSINESS SEGMENTS (UNAUDITED)
The company operates in two primary business segments: North
America and Europe with each selling the company's primary product
categories, which includes: lifestyle, mobility and seating and
respiratory therapy products. Sales in Asia Pacific, which do not
meet the quantitative criteria for determining reportable segments,
are reported in All Other and include products similar to those
sold in North America and Europe. Intersegment revenue for
reportable segments was $30,768,000 and $84,439,000 for the three
and nine months ended September 30, 2020 compared to $28,158,000
and $81,281,000 for the three and nine months ended September 30,
2019. The accounting principles applied at the operating segment
level are generally the same as those applied at the consolidated
financial statement level. Intersegment sales are eliminated in
consolidation.
The information by segment is as follows:
Three Months Ended
Nine Months Ended
(In thousands)
September 30
September 30
2020
2019
Change
2020
2019
Change
Revenues from external customers
Europe
$
116,285
$
137,371
$
(21,086
)
$
339,147
$
396,206
$
(57,059
)
North America
88,055
87,118
937
261,595
262,915
(1,320
)
All Other (sales in Asia Pacific)
7,566
11,285
(3,719
)
25,904
35,930
(10,026
)
Consolidated
$
211,906
$
235,774
$
(23,868
)
$
626,646
$
695,051
$
(68,405
)
Operating income (loss)
Europe
$
7,600
$
11,365
$
(3,765
)
$
16,624
$
22,617
$
(5,993
)
North America
2,992
(1,694
)
4,686
5,759
(7,316
)
13,075
All Other*
(6,082
)
(5,625
)
(457
)
(17,377
)
(18,230
)
853
Charge related to restructuring
activities
(1,580
)
(1,628
)
48
(4,657
)
(3,641
)
(1,016
)
Gain on sale of business
—
—
—
9,790
—
9,790
Consolidated operating income (loss)
2,930
2,418
512
10,139
(6,570
)
16,709
Net gain on convertible debt
derivatives
—
—
—
—
1,197
(1,197
)
Loss on debt extinguishment including debt
finance charges and fees
(761
)
(280
)
(481
)
(7,360
)
(280
)
(7,080
)
Net interest expense
(7,395
)
(6,879
)
(516
)
(21,042
)
(21,666
)
624
Loss before income taxes
$
(5,226
)
$
(4,741
)
$
(485
)
$
(18,263
)
$
(27,319
)
$
9,056
* “All Other” consists of operating income (loss) associated
with the company's businesses in the Asia Pacific region and
unallocated corporate selling, general and administrative
("SG&A") expenses and intersegment eliminations, which do not
meet the quantitative criteria for determining reportable
segments.
INVACARE CORPORATION AND SUBSIDIARIES
BUSINESS SEGMENT NET SALES (UNAUDITED)
The following tables provide net sales changes by segment as
reported and as adjusted to exclude the impact of foreign exchange
translation and divestitures (constant currency net sales(a)) for
the three-month and nine-month periods referenced below. The
current year constant currency net sales are translated using the
prior year's foreign exchange rates. These amounts are then
compared to the prior year's sales to calculate the constant
currency net sales change.
Three months ended September 30, 2020 compared to September 30,
2019:
Reported
Foreign Exchange
Translation Impact
Divestiture Impact
Constant Currency
Europe
(15.3
)%
2.2
%
—
%
(17.5
)%
North America
1.1
(0.1
)
—
1.2
All Other (sales in Asia Pacific)
(33.0
)
3.2
(33.1
)
(3.1
)
Consolidated
(10.1
)%
1.5
%
(1.6
)%
(10.0
)%
Nine months ended September 30, 2020 compared to September 30,
2019:
Reported
Foreign Exchange
Translation Impact
Divestiture Impact
Constant Currency
Europe
(14.4
)%
(1.1
)%
—
%
(13.3
)%
North America
(0.5
)
(0.2
)
—
(0.3
)
All Other (sales in Asia Pacific)
(27.9
)
(3.5
)
(26.9
)
2.5
Consolidated
(9.8
)%
(0.7
)%
(1.4
)%
(7.7
)%
INVACARE CORPORATION AND SUBSIDIARIES
BUSINESS SEQUENTIAL SEGMENT NET SALES (UNAUDITED)
The following table provides net sales at reported rates for the
quarters ended September 30, 2020 and June 30, 2020, respectively,
and net sales of the quarter ended September 30, 2020 as translated
at the foreign exchange rates for the quarter ended June 30, 2020
with each then compared to each other (constant currency sequential
net sales(b)). The company is including this disclosure to
illustrate the effect of the pandemic on its segments' net
sales.
Three months ended September 30, 2020 compared to June 30,
2020:
3Q20 at
Reported
Exchange
Rates
Foreign
Exchange
Translation
Impact
3Q20 at
2Q20
Foreign
Exchange
Rates
2Q20 at
Reported
Foreign
Exchange
Rates
Sequential
Growth $
Sequential
Growth %
Europe
$
116,285
$
(6,276
)
$
110,009
$
101,894
$
8,115
8.0
%
North America
88,055
(342
)
87,713
86,569
1,144
1.3
All Other (sales in Asia Pacific)
7,566
(534
)
7,032
7,837
(805
)
(10.3
)
Consolidated
$
211,906
$
(7,152
)
$
204,754
$
196,300
$
8,454
4.3
%
INVACARE CORPORATION AND
SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE
SHEET (UNAUDITED)
(In thousands)
September 30, 2020
December 31, 2019
Assets
Current Assets
Cash and cash equivalents
$
86,825
$
80,063
Trade receivables, net
108,957
116,669
Installment receivables, net
261
736
Inventories, net
145,452
120,500
Other current assets
37,635
37,909
Total Current Assets
379,130
355,877
Other Assets
3,991
4,216
Intangibles
27,770
26,447
Property and Equipment, net
53,112
46,607
Financing Lease Assets, net
65,108
26,900
Operating Lease Assets, net
13,075
18,676
Goodwill
401,665
373,403
Total Assets
$
943,851
$
852,126
Liabilities and Shareholders’
Equity
Current Liabilities
Accounts payable
$
93,160
$
88,003
Accrued expenses
124,666
120,947
Current taxes payable
2,197
345
Current portion of financing lease
obligations
3,352
2,514
Current portion of operating lease
obligations
5,843
6,790
Short-term debt and current maturities of
long-term obligations
4,062
58
Total Current Liabilities
233,280
218,657
Long-Term Debt
238,202
219,464
Long-Term Obligations - Financing
Leases
63,950
26,480
Long-Term Obligations - Operating
Leases
7,182
12,060
Other Long-Term Obligations
70,748
66,949
Shareholders’ Equity
330,489
308,516
Total Liabilities and Shareholders’
Equity
$
943,851
$
852,126
INVACARE CORPORATION AND
SUBSIDIARIES
RECONCILIATION FROM NET CASH
PROVIDED (USED) BY
OPERATING ACTIVITIES TO FREE
CASH FLOW(g)
Three Months Ended
Nine Months Ended
(In thousands)
September 30
September 30
2020
2019
2020
2019
Net cash provided (used) by operating
activities
$
4,147
$
15,121
$
822
$
(4,732
)
Plus:
Sales of property and equipment
3
9
396
73
Less:
Purchases of property and equipment
(5,945
)
(2,856
)
(16,824
)
(7,177
)
Free Cash Flow(g) (usage)
$
(1,795
)
$
12,274
$
(15,606
)
$
(11,836
)
Three Months Ended
(In thousands)
September 30
June
30
2020
2020
Net cash provided by operating
activities
$
4,147
$
6,514
Plus:
Sales of property and equipment
3
389
Less:
Purchases of property and equipment
(5,945
)
(8,758
)
Free Cash Flow(g) (usage)
$
(1,795
)
$
(1,855
)
"Free Cash Flow(g) is a non-GAAP financial measure, which is
defined at the end of this press release.
Definitions of Non-GAAP Financial Measures
(a) "Constant currency net sales" is a non-GAAP financial
measure, which is defined as net sales excluding the impact of
foreign currency translation and further adjusted to exclude the
impact of the sale of Dynamic Controls, which was sold in March
2020 and not deemed a discontinued operation for financial
reporting purposes. The current year's functional constant currency
net sales are translated using the prior year's foreign exchange
rates. These amounts are then compared to the prior year's sales to
calculate the constant currency net sales change. The "Business
Segments Net Sales" table accompanying this press release compares
net sales as reported and net sales excluding the effects of
foreign exchange translation by segment and for the consolidated
company for the three and nine months ended September 30, 2020 and
September 30, 2019, respectively. The company believes that this
financial measure provides meaningful information for evaluating
the core operating performance of the company. This financial
measure is reconciled to the related GAAP financial measures in the
"Business Segment Net Sales" table included in this press
release.
(b) "Constant currency sequential net sales" is a non-GAAP
financial measure, in which a given quarter's net sales are
compared to the most recent prior quarter's net sales with each
quarter's net sales translated at the foreign exchange rates for
the most recent prior quarter. The company believes that this
financial measure provides meaningful information for evaluating
the core operating performance of the company. This financial
measure is reconciled to the related GAAP financial measures in the
"Business Segment Net Sales" table included in this press
release.
(c) "Constant Currency SG&A" is a non-GAAP financial
measure, which is defined as selling, general and administrative
("SG&A") expense excluding the impact of foreign currency
translation and further adjusted to exclude the impact of the sale
of Dynamic Controls, which was sold in March 2020 and not deemed a
discontinued operation for financial reporting purposes. The
current period's functional constant currency SG&A expenses are
translated using the prior year's foreign exchange rates. These
amounts are then compared to the prior year's SG&A expenses to
calculate the constant currency SG&A expenses change.
(d) "Constant currency sequential SG&A" is a non-GAAP
financial measure, which is defined as selling, general and
administrative ("SG&A") expense excluding the impact of foreign
currency translation. The current quarter's functional constant
currency SG&A expenses are translated using the prior quarter's
foreign exchange rates. These amounts are then compared to the
prior quarter's SG&A expenses to calculate the constant
currency sequential SG&A change.
(e) "Adjusted net loss per share" is a non-GAAP financial
measure, which is defined as adjusted net loss(h) divided by
weighted average shares outstanding, assuming dilution. It should
be noted that the company's definition of adjusted net loss per
share may not be comparable to similar measures disclosed by other
companies because not all companies and financial analysts
calculate adjusted net loss per share in the same manner. The
company believes that its exclusion adjustments are generally
recognized by the industry in which it operates as relevant in
computing Adjusted net loss per share as a supplementary non-GAAP
financial measure used by financial analysts and others in the
company's industry to meaningfully evaluate operating performance.
This financial measure is reconciled to the related GAAP financial
measure in the “Reconciliation of Net Earnings (Loss) Per Share to
Adjusted Net Loss per Share” table included in this press
release.
(f) "Adjusted EBITDA" is a non-GAAP financial measure, which is
defined as earnings before interest, taxes, depreciation and
amortization and calculated as net loss plus: income taxes,
interest expense-net, net gain or loss on convertible debt
derivatives, loss on debt extinguishment including debt finance
charges and fees, net gain on sale of business, and depreciation
and amortization, as further adjusted to exclude charges related to
restructuring activities, and share-based compensation expense. It
should be noted that the company's definition of Adjusted EBITDA
may not be comparable to similar measures disclosed by other
companies because not all companies and financial analysts
calculate Adjusted EBITDA in the same manner. The company believes
that this financial measure provides meaningful information which
is used by financial analysts and others in the company's industry
to evaluate the performance of the company. This financial measure
is reconciled to the related GAAP financial measure in the
“Reconciliation of Net Loss to Adjusted EBITDA” table included in
this press release.
(g) "Free cash flow" is a non-GAAP financial measure, which is
defined as net cash provided (used) by operating activities less
purchases of property and equipment plus proceeds from sales of
property and equipment. The company believes that this financial
measure provides meaningful information for evaluating the overall
financial performance of the company and its ability to repay debt
or make future investments. This financial measure is reconciled to
the related GAAP financial measure in the “Reconciliation from Net
Cash Used by Operating Activities to Free Cash Flow” table included
in this press release.
(h) "Adjusted net loss" is a non-GAAP financial measure, which
is defined as net loss before income tax provision and excluding
the amortization of convertible debt discounts recorded in interest
expense ($3.0 million and $8.6 million pre-tax for the three and
nine months ended September 30, 2020 and $2.8 million and $9.4
million for the three and nine months ended September 30, 2019),
loss on debt extinguishment including debt finance charges and fees
($0.8 million and $7.4 million pre-tax for the three and nine
months ended September 30, 2020 and $0.3 million for the three and
nine months ended September 30, 2019), gain on sale of business
($0.0 million and $9.8 million pre-tax for the three and nine
months ended September 30, 2020), net gain on convertible debt
derivatives ($0.0 million and $1.2 million for the three and nine
months ended September 30, 2019), and adjusted income taxes.
Adjusted income taxes are computed as taxes as calculated for GAAP
then adjusted for an expense or benefit at the statutory rate
related to pretax adjustments related to locations without a
valuation allowance, the exclusion of uncertain tax liabilities
deemed not related to current operations or the exclusion of taxes
related to nonrecurring sales of non-inventory product or entities
on an intercompany basis as well as the impact from the sale of
Dynamic Controls, which was sold in March 2020. (Note: The U.S. is
in a full valuation allowance and accordingly, no tax expense
adjustments are appropriate related to U.S. pre-tax adjustments.)
This financial measure is reconciled to the related GAAP financial
measure in the “Reconciliation of Net Earnings (Loss) per Share to
Adjusted Net Loss Per Share” table included in this press
release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201029006275/en/
Lois Lee loislee@invacare.com 440-329-6435
Invacare (NYSE:IVC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Invacare (NYSE:IVC)
Historical Stock Chart
From Sep 2023 to Sep 2024